Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 11/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 9/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | G6PD | P11413 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.31 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.31 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.31 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23256252 | 0.89 | NPC1 (0.37) | NPC1LMNARAB9ASMN1; SMN2CRBN | |
| SCHEMBL909830 | 0.68 | NPC1 (0.44) | NPC1LMNARAB9ASMN1; SMN2CRBN | |
| SCHEMBL25792210 | 0.67 | NPC1 (0.54) | NPC1LMNARAB9ASMN1; SMN2CRBN | |
| SCHEMBL13114252 | 0.67 | CYP11B2 (0.57) | NPC1LMNARAB9ASMN1; SMN2CRBN | |
| SCHEMBL15473978 | 0.65 | — | — | |
| SCHEMBL1713993 | 0.65 | CRBN (0.37) | NPC1LMNARAB9ASMN1; SMN2CRBN | |
| SCHEMBL3980439 | 0.65 | MAPT (0.36) | LMNARAB9AALOX12 | |
| SCHEMBL24439824 | 0.64 | KDM4E (0.32) | — | |
| SCHEMBL3710781 | 0.64 | — | — | |
| SCHEMBL24800708 | 0.63 | CYP11B2 (0.50) | NPC1LMNARAB9ASMN1; SMN2CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4161494-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| US-9844553-B2 | Pyrazolopyridyl compounds as aldosterone synthase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-12-19 | — | — | US | disclosed |
| US-20170020879-A1 | PYRAZOLOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC | 2017-01-26 | — | — | US | disclosed |
| EP-0332156-B1 | Cephem compounds and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 1996-12-18 | — | — | EP | disclosed |
| US-5366970-A | Cephem compounds and pharmaceutically acceptable salts thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-22 | — | — | US | disclosed |
| US-5173485-A | Bactericides, microbiocides | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1992-12-22 | — | — | US | disclosed |
| EP-0332156-A2 | Cephem compounds and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170020879-A1 | PYRAZOLOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP11B2, CYP11B1 | NPC1 1320/4885LMNA 2356/4885RAB9A 4124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.